Search results
Showing 1 to 15 of 42 results for botulinum toxin type a
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
Chronic anal fissure: botulinum toxin type A injection (ESUOM14)
Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making
In development [GID-TA10992] Expected publication date: 15 May 2024
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.
View recommendations for IPG766Show all sections
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
Botulinum toxin type A for preventing episodic migraine TS ID 11939
Awaiting development [GID-TA11505] Expected publication date: TBC
CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used...
Question Method of botulinum toxin type A injection in treating focal spasticity:- Is guided botulinum toxin type A...
What is the long-term effectiveness of bladder wall injection with botulinum toxin type A for overactive bladder in women? Any...